AGP100
/ Agiana Pharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 27, 2025
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
(clinicaltrials.gov)
- P2 | N=10 | Recruiting | Sponsor: Agiana Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Ventricular Tachycardia
December 05, 2025
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
(clinicaltrials.gov)
- P2 | N=10 | Not yet recruiting | Sponsor: Agiana Pharmaceuticals
New P2 trial • Cardiovascular • Ventricular Tachycardia
1 to 2
Of
2
Go to page
1